Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721351 · ClinicalTrials.gov registry record · NA
Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence
A NA study of Diabetic Retinopathy (DR), sponsored by Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health.
- Active
- Registry status
- NA
- Development phase
- 548
- Enrollment target
- 3
- Study locations
NCT06721351 is a NA study of Diabetic Retinopathy (DR) that is active but no longer recruiting, run by Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health. The registered enrollment target is 548 participants, above the 400-participant average among 5 other Diabetic Retinopathy (DR) trials with a reported enrollment target (37% higher). The trial reports 3 study locations across 1 state.
The verdict
NCT06721351, a NA study of Diabetic Retinopathy (DR), is active but no longer recruiting, sponsored by Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 548 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is being conducted to improve eye care by using artificial intelligence (AI) to make diabetic eye screenings faster and more accessible. AI technology mimics human decision-making, enabling computers and systems to analyze medication information. Specifically for this screening, AI examines digital images of the eye and based on that information, may identify if a participant has diabetic retinopathy. It can assist doctors in making decisions about a participant's diagnosis, treatment or care plans to improve patient care. This is a collaboration between San Ysidro Health (SYHealth), University of California, San Diego (UC San Diego), and Eyenuk. The Kaiser Permanente Augmented Intelligence in Medicine and Healthcare Initiative (AIM-HI) awarded SYHealth funds to demonstrate the value of AI technologies in diverse, real-world settings.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diabetic Retinopathy screening Point of Care Artificial Intelligence
Study Locations (3)
California
- San Ysidro Health Chula Vista - Chula Vista
- San Ysidro Health - Comprehensive Health Center - Ocean View - San Diego
- San Ysidro Health King-Chavez Health Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 548 participants |
| Start Date | 2024-07-27 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721351
The ClinicalTrials.gov registry entry for NCT06721351 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 548 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 400-participant average among 5 other Diabetic Retinopathy (DR) trials with a reported enrollment target (37% higher). The listed sponsor is Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy (DR) appearing as the primary indexed condition, and to 1 intervention - of which Diabetic Retinopathy screening Point of Care Artificial Intelligence is the first listed.
NCT06721351 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06721351 about?
NCT06721351 is a clinical study titled "Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence". This research study is being conducted to improve eye care by using artificial intelligence (AI) to make diabetic eye screenings faster and more accessible. AI technology mimics human decision-making, enabling computers and systems to analyze medication information. Specifically for this screening, ...
What is the current status of trial NCT06721351?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 548 participants. The study started on 2024-07-27. Estimated completion is 2026-04-30.
What conditions does trial NCT06721351 study?
This clinical trial studies the following conditions: Diabetic Retinopathy (DR).
What interventions are being tested in trial NCT06721351?
The interventions under investigation include: Diabetic Retinopathy screening Point of Care Artificial Intelligence (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06721351?
This trial is sponsored by Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721351 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy (DR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)
RECRUITING · NA
-
Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images
COMPLETED · NA
-
Assessment of AI Program 'DRISTi' as a Screening Tool
RECRUITING
-
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ACTIVE NOT RECRUITING · Phase 2
-
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.